Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any supplement regimen or making changes to your health routine. The information presented here is based on published research but should not replace professional medical guidance.
What Is Resveratrol?
Resveratrol is a polyphenolic compound — specifically a stilbenoid — produced naturally by certain plants under stress, UV radiation, or fungal attack. You’ll find it in the skin of red grapes, blueberries, peanuts, and most famously in red wine. The compound exists in two isomeric forms: trans-resveratrol and cis-resveratrol, with the trans form being the biologically active one that dominates the research literature.
Interest in resveratrol as a longevity molecule exploded in the early 2000s, largely because of the work of David Sinclair at Harvard — whose broader anti-aging protocol I’ve written about separately — and the tantalising hypothesis that resveratrol might mimic some of the cellular effects of caloric restriction. For a time, it was the most hyped anti-aging supplement on the planet. The story since then has been considerably more nuanced.
I’ve been tracking resveratrol research since the mid-2000s and have taken it myself at various points over that period. My honest position: it’s a genuinely interesting molecule with real biological activity, but the leap from “fascinating in the lab” to “proven human longevity supplement” is one the current evidence doesn’t fully support. Let me walk you through what we actually know.
Mechanism of Action: How It Works at the Cellular Level
Resveratrol’s proposed mechanisms are multiple, which is part of what makes it scientifically compelling — and part of what makes interpretation difficult. Here are the primary pathways that have credible evidence behind them.
Sirtuin Activation (SIRT1)
The most discussed mechanism is activation of SIRT1, a NAD⁺-dependent deacetylase enzyme that regulates gene expression, DNA repair, mitochondrial biogenesis, and inflammatory response. Sirtuins are often described as longevity genes; caloric restriction activates them, and resveratrol was initially proposed to be a sirtuin-activating compound (STAC). The original 2003 Howitz et al. paper in Nature (PMID: 14551312) suggested resveratrol could activate SIRT1 directly. This was later contested — some researchers argued the activation was an artefact of the fluorescent assay used — though subsequent work using more refined assays has supported meaningful SIRT1 interaction in physiological conditions.
AMPK Activation
Resveratrol appears to activate AMP-activated protein kinase (AMPK), a master energy-sensing enzyme that suppresses anabolic processes when cellular energy is low. AMPK activation is associated with improved insulin sensitivity, reduced lipid synthesis, and enhanced autophagy — the cellular “housekeeping” process that clears damaged proteins and organelles. This is arguably the best-supported mechanistic pathway in human tissue.
mTOR Inhibition
By activating AMPK, resveratrol indirectly inhibits mTORC1, the mechanistic target of rapamycin complex 1. Excessive mTOR signalling is linked to accelerated cellular ageing; inhibiting it is one of the most robust interventions for extending lifespan across model organisms. If you’re familiar with NMN research, you’ll recognise this as part of the same NAD⁺/sirtuin/AMPK network that multiple longevity researchers are targeting simultaneously.
Anti-Inflammatory and Antioxidant Activity
Resveratrol downregulates NF-κB signalling, one of the central drivers of chronic low-grade inflammation (“inflammageing”). It also reduces reactive oxygen species (ROS) production, though it’s worth noting that its direct antioxidant capacity in vivo is considerably weaker than its in vitro profile suggests — partly because of poor bioavailability.
Telomere and DNA Repair Effects
Some evidence suggests resveratrol may support telomere maintenance and upregulate certain DNA repair pathways. This remains an area of active investigation and the human data here is thin.
What the Research Actually Shows
This is the section where I have to be honest with you about the gap between the headline-grabbing animal studies and the more modest human trial data.
The Animal Data: Genuinely Compelling
The 2006 Baur et al. study published in Nature (PMID: 17086191) showed that resveratrol supplementation extended the lifespan of obese mice fed a high-fat diet, improved their insulin sensitivity, and enhanced mitochondrial function — effects the authors likened to caloric restriction. In yeast, worms, and fruit flies, lifespan extension with resveratrol has been demonstrated multiple times. These aren’t trivial results. They point to real biological activity through conserved pathways.
However — and this is important — subsequent studies in non-obese mice showed no significant lifespan extension. The benefit in the Baur study appeared specific to countering metabolic dysfunction. This matters because most resveratrol consumers are not obese mice on a 60% fat diet.
Human Cardiovascular Trials
A randomised controlled trial by Bhatt et al. and the more widely cited work by Tomé-Carneiro et al. (PMID: 22895891) examined resveratrol’s effects on cardiovascular risk factors in patients with stable coronary artery disease. Over one year, the resveratrol group showed favourable changes in inflammatory markers including TNF-α and IL-6/IL-1β ratios, as well as improvements in LDL oxidation. These are meaningful endpoints, not surrogate biomarkers conjured from obscurity.
A systematic review and meta-analysis by Liu et al. (PMID: 25158730) pooled data from randomised trials and found that resveratrol supplementation significantly reduced systolic blood pressure when used at higher doses (≥300 mg/day), though effects on diastolic pressure and lipid profiles were inconsistent across trials.
Metabolic Health and Type 2 Diabetes
This is probably the area with the strongest human trial signal. A 2011 trial by Bhatt et al. published in Nutrition Research (PMID: 21419319) demonstrated that 250 mg/day of resveratrol for three months in type 2 diabetic patients improved HbA1c, fasting glucose, and insulin sensitivity. A meta-analysis by Hausenblas et al. (PMID: 25172906) confirmed a statistically significant effect on fasting glucose and insulin sensitivity across multiple trials. The effect sizes are modest — resveratrol is not replacing metformin — but they are real and reproducible.
Cognitive Function
A double-blind, placebo-controlled trial by Turner et al. (PMID: 25760553) in postmenopausal women found that 75 mg twice daily of resveratrol over 14 weeks improved cerebrovascular function and cognitive performance on specific tasks. This is intriguing data, though the trial was relatively small (80 participants) and the effect sizes were modest.
The Sinclair Lab Controversy
I won’t relitigate the entire academic dispute here, but it’s worth noting that Pfizer’s purchase of Sirtris Pharmaceuticals (Sinclair’s resveratrol-focused company) for $720 million in 2008 was followed by the discontinuation of their resveratrol-based drug pipeline by 2013, largely due to safety concerns with synthetic analogues and disappointing trial results. The David Sinclair protocol has since shifted substantially toward NMN/NR as the primary NAD⁺-boosting strategy, with resveratrol retained as a SIRT1 activator in combination.
Dosage: What the Clinical Trials Used
One of the frustrations with resveratrol research is the wide range of doses used across trials, making direct comparisons difficult. Here’s a summary of what the evidence supports:
| Target Outcome | Dose Used in Trials | Duration | Evidence Quality |
|---|---|---|---|
| Glucose/insulin sensitivity | 150–500 mg/day | 8–16 weeks | Moderate (multiple RCTs) |
| Cardiovascular inflammation | 100–350 mg/day | 12–52 weeks | Moderate (several RCTs) |
| Blood pressure (systolic) | ≥300 mg/day | 8–12 weeks | Low-moderate (meta-analysis) |
| Cognitive function | 150 mg/day (75 mg twice daily) | 14 weeks | Low (single RCT) |
| General anti-aging/longevity | Not established | Not established | No human RCT evidence |
My personal approach has been 250–500 mg of trans-resveratrol daily, taken with a fatty meal to improve absorption. Some researchers advocate splitting the dose across the day given resveratrol’s short half-life of around 1–3 hours. I find this impractical and there’s no strong clinical data mandating it.
Forms and Bioavailability: A Comparison
Not all resveratrol supplements are equivalent. The form, purity, and delivery system matter considerably given the bioavailability challenges discussed above.
| Form | Key Feature | Bioavailability vs Standard | Cost | Notes |
|---|---|---|---|---|
| Standard trans-resveratrol (powder/capsule) | Most common; source is usually Japanese knotweed (Polygonum cuspidatum) | Baseline | Low–moderate | Purity varies widely; look for ≥98% trans-resveratrol on CoA |
| Micronised resveratrol | Reduced particle size increases surface area for absorption | ~1.5–2× standard | Moderate | Limited head-to-head human data but pharmacokinetically plausible |
| Resveratrol + piperine | Piperine inhibits sulphation enzymes, slowing metabolism | ~1.5–2× standard | Low–moderate | Piperine affects drug metabolism broadly — caution if on medications |
| Phospholipid-complexed (e.g., Meriva-style) | Bound to phosphatidylcholine for enhanced gut absorption | ~3–5× standard (curcumin analogy) | Higher | Less resveratrol-specific data than curcumin analogues; promising |
| Liposomal resveratrol | Encapsulated in lipid nanoparticles | Potentially significant improvement | Highest | Clinical data limited; technology promising but evidence lags marketing claims |
| Pterostilbene (resveratrol analogue) | Dimethylated version of resveratrol; higher bioavailability, longer half-life | Substantially higher (~4× oral bioavailability) | Moderate–high | Fewer human trials than resveratrol itself; may raise LDL at high doses |
Of these, I currently use a micronised trans-resveratrol from a supplier that provides third-party certificates of analysis. I’ve used pterostilbene as well and find the pharmacokinetic argument for it compelling — but the human trial base is thinner, and the LDL-raising signal at doses above 250 mg/day gives me pause.
Side Effects and Safety
Resveratrol has a generally good short-term safety profile at doses used in clinical trials. That said, “generally well tolerated in 12-week trials” is not the same as “proven safe for indefinite daily use,” and I think it’s important to be clear about that distinction.
Common and Reported Side Effects
- Gastrointestinal symptoms: Nausea, loose stools, and abdominal discomfort are the most frequently reported adverse effects, particularly at doses above 1,000 mg/day. Starting at a lower dose and titrating up is sensible.
- Headache: Reported in some trial participants, mechanism unclear.
- Joint pain: Flagged in some longer-term trials, though causality is uncertain.
The Hormesis Question
There’s emerging discussion — including a provocative analysis by Gliemann et al. (PMID: 23954173) — that high-dose resveratrol may actually blunt the cardiovascular adaptations to exercise training by interfering with the reactive oxygen species signalling that drives training adaptation. If you exercise regularly for health, this finding is worth taking seriously. The study was in older men and used 250 mg/day. Replication is needed, but I take rest days from resveratrol on heavy training days partly in response to this.
Drug Interactions
- Anticoagulants (warfarin, apixaban): Resveratrol inhibits platelet aggregation and may potentiate anticoagulant effects. Do not combine without medical supervision.
- CYP450 enzyme substrates: Resveratrol inhibits CYP3A4 and CYP2D6 at higher doses, potentially affecting blood levels of numerous medications including statins, calcium channel blockers, and certain antidepressants.
- Oestrogen-sensitive conditions: Resveratrol has mild phytooestrogenic activity. Its clinical significance is debated, but individuals with hormone-sensitive cancers should discuss use with their oncologist.
Who Should Consider a Resveratrol Supplement?
Based on where the evidence is strongest, the following groups have the most plausible case for benefit:
- Adults with impaired fasting glucose or insulin resistance: This is the area with the most consistent human RCT signal. Resveratrol as an adjunct — not a replacement for dietary changes and exercise — is reasonable.
- Individuals with elevated cardiovascular inflammatory markers: If you have high CRP, elevated IL-6, or have been told you have endothelial dysfunction, the cardiovascular data is worth considering.
- Postmenopausal women: The Turner et al. cognitive trial specifically recruited this population, and the cerebrovascular effects are biologically plausible given oestrogen’s known cardiovascular-protective role.
- Those following a NAD⁺-focused longevity stack: If you’re already using NMN or NR, adding resveratrol as a SIRT1 activator is consistent with the mechanistic logic, even if the synergy in humans remains largely theoretical.
Who Should Avoid It or Proceed With Caution
- Anyone on anticoagulant therapy without medical oversight
- Individuals taking medications metabolised by CYP3A4 or CYP2D6
- Those with hormone-sensitive cancers (breast, ovarian, endometrial)
- Pregnant or breastfeeding women (insufficient safety data)
- Serious competitive athletes whose training adaptations are a priority (based on the Gliemann finding, I’d at least time supplementation away from training sessions)
My Honest Verdict
After 20-plus years of following this research and a good chunk of that time taking resveratrol myself, here’s where I land:
Resveratrol is a genuinely bioactive compound with plausible longevity mechanisms and real, if modest, human trial evidence in metabolic and cardiovascular health. It is not the “red wine longevity pill” it was briefly marketed as in the late 2000s, and anyone still presenting it that way isn’t being straight with you. The failure of Sirtris’s drug programme should give pause to anyone expecting dramatic effects.
What resveratrol appears to offer is a meaningful biological nudge in the right direction for people with metabolic risk factors — improved insulin sensitivity, reduced inflammatory markers, possibly some cerebrovascular benefit. These are not nothing. In a landscape where many popular supplements have zero credible human trial data, resveratrol is above average on the evidence hierarchy.
The honest caveats: bioavailability is a real limitation with standard formulations; the exercise interference data deserves attention; indefinite long-term safety in humans hasn’t been established; and the most dramatic longevity results remain in model organisms, not clinical trials.
My current practice: 250 mg of micronised trans-resveratrol daily, with breakfast, on non-heavy-training days. I don’t take it with the expectation it’s extending my lifespan directly — I take it because the metabolic and vascular data is credible and the risk profile at this dose appears acceptable. That’s a very different framing than the longevity-pill narrative, but it’s the honest one.
Frequently Asked Questions
Does resveratrol actually extend human lifespan?
There is currently no randomised controlled trial evidence that resveratrol extends lifespan in healthy humans. Lifespan extension has been demonstrated in yeast, worms, fruit flies, and obese mice, but replication in non-obese mammals has been inconsistent. Conducting a lifespan trial in humans is practically impossible. What we can say is that resveratrol positively influences several biological pathways — insulin sensitivity, inflammatory markers, SIRT1/AMPK signalling — that are associated with healthier ageing. That’s a meaningful but importantly different claim from “it extends your life.”
What is the best dose of resveratrol to take?
Clinical trials have used doses ranging from 75 mg to 2,000 mg per day. The strongest metabolic effects in human trials appear at 150–500 mg/day. Blood pressure benefits in meta-analyses emerge more clearly at 300 mg/day and above. I would suggest starting at 150–250 mg/day with a fatty meal and only increasing if well tolerated. There is no strong evidence that doses above 500 mg/day provide proportionally greater benefit, and gastrointestinal side effects become more common above 1,000 mg/day.
Is resveratrol better than pterostilbene?
Pterostilbene is a dimethylated analogue of resveratrol with substantially higher oral bioavailability — estimated at around four times that of standard resveratrol — and a longer biological half-life. Mechanistically, it’s very similar. However, resveratrol has a considerably larger human clinical trial database. Pterostilbene also has a flagged concern around LDL cholesterol elevation at doses above 250 mg/day in some trials. My view: pterostilbene’s pharmacokinetics are attractive, but the thinner human evidence base and the LDL signal mean I wouldn’t automatically prefer it over well-sourced resveratrol. If cost isn’t a barrier and you’re not at cardiovascular risk, it’s a reasonable alternative worth monitoring as the evidence base grows.
Can I get enough resveratrol from red wine?
No — not at doses used in clinical trials. A glass of red wine contains roughly 0.3 to 1.9 mg of resveratrol. To reach the 150–500 mg used in metabolic health trials, you’d need to drink somewhere between 80 and 1,500 glasses per day. The alcohol-related harm from any such attempt would vastly outweigh any conceivable resveratrol benefit. The “red wine is good for you because of resveratrol” narrative is not supported by the dosing arithmetic. If red wine has cardiovascular benefits, they are more likely attributable to other polyphenols, social context, or drinking patterns rather than resveratrol specifically.
Should I take resveratrol with NMN?
This combination is used by David Sinclair and others in the longevity field. The mechanistic rationale is that NMN raises intracellular NAD⁺ levels, while resveratrol activates SIRT1 — the NAD⁺-dependent enzyme that is central to many proposed longevity effects. In theory, they work synergistically: more fuel (NAD⁺) and a more active enzyme (SIRT1). In practice, human trial data testing this specific combination is limited. Both compounds have reasonable individual evidence bases. I use them together and find the combination theoretically coherent, but I want to be honest: the synergy claim in humans is still largely extrapolated from animal and in vitro work.
Does resveratrol interfere with exercise?
This is a genuinely important question that most resveratrol articles gloss over. A 2013 study by Gliemann et al. (PMID: 23954173) found that 250 mg/day of resveratrol in healthy older men actually blunted several positive cardiovascular adaptations to exercise training — including improvements in VO₂ max and mitochondrial function. The proposed mechanism is that resveratrol’s antioxidant activity mops up the reactive oxygen species that are necessary signals for training adaptation. This finding has not been consistently replicated, but it is credible enough that I take it seriously. My personal approach is to avoid resveratrol on days of intense training, though this remains a precautionary rather than definitively evidence-based recommendation.
Citations
- Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425(6954):191–196. PMID: 14551312
- Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337–342. PMID: 17086191
- Tomé-Carneiro J, Gonzalvez M, Larrosa M, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012;110(3):356–363. PMID: 22895891
- Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015;34(1):27–34. PMID: 25158730
- Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32(7):537–541. PMID: 21419319
- Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus — systematic review and meta-analysis. Mol Nutr Food Res. 2015;59(1):147–159. PMID: 25172906
- Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383–